Milatuzumab
- Generic Name
- Milatuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 899796-83-9
- Unique Ingredient Identifier
- 2OP4E0GC6V
- Background
Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
STRO-001, a novel antibody-drug conjugate targeting CD74, shows promising anti-tumor activity in multiple myeloma (MM) models. It effectively reduces tumor burden and prolongs survival in MM xenograft models, with dose-dependent efficacy and reversible B-cell and monocyte depletion in cynomolgus monkeys. CD74 expression is prevalent in MM, making it a viable therapeutic target.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath